fluconazole has been researched along with Body Weight in 25 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In preterm neonates, fluconazole clearance is best predicted by actual body weight and serum creatinine concentration." | 8.12 | Optimisation of fluconazole therapy for the treatment of invasive candidiasis in preterm infants. ( Alffenaar, JC; Brüggemann, RJ; Engbers, AGJ; Flint, RB; Knibbe, CAJ; Liem, KD; Reiss, I; Simons, S; Tibboel, D; Voeller, S, 2022) |
| " Fluconazole clearance was dependent on creatinine clearance, and volume of distribution was dependent on body weight and age." | 5.10 | Enteral fluconazole population pharmacokinetics in patients in the surgical intensive care unit. ( Hendrix, CW; Lipsett, PA; Pelz, RK; Rajagopalan, P; Rinaldi, MG; Swoboda, SM, 2003) |
| "In preterm neonates, fluconazole clearance is best predicted by actual body weight and serum creatinine concentration." | 4.12 | Optimisation of fluconazole therapy for the treatment of invasive candidiasis in preterm infants. ( Alffenaar, JC; Brüggemann, RJ; Engbers, AGJ; Flint, RB; Knibbe, CAJ; Liem, KD; Reiss, I; Simons, S; Tibboel, D; Voeller, S, 2022) |
| "In our population of obese but otherwise healthy individuals, obesity clearly alters the pharmacokinetics of fluconazole, which puts severely obese adults, particularly if male, at risk of suboptimal exposure, for which adjusted doses are proposed." | 4.12 | Total bodyweight and sex both drive pharmacokinetic variability of fluconazole in obese adults. ( Brüggemann, RJ; Chen, L; Knibbe, CAJ; Krekels, EHJ; van der Linden, PD; van Dongen, EPA; van Rhee, KP; Verweij, PE; Wasmann, RE; Wiezer, MJ, 2022) |
| "Mortality was associated with Glasgow coma score (GCS) below 15 (adjusted Hazard ratio (aHR) 1." | 2.94 | Determinants of two-year mortality among HIV positive patients with Cryptococcal meningitis initiating standard antifungal treatment with or without adjunctive dexamethasone in Uganda. ( Anywaine, Z; Day, J; Ggayi, AB; Kaleebu, P; Kibengo, FM; Kitonsa, J; Kiwanuka, J; Mayanja, Y; Nikweri, Y; Nsubuga, R; Onyango, M, 2020) |
| "0 L and the bioavailability (F) was 81." | 2.90 | Multicenter-Based Population Pharmacokinetic Analysis of Ciclosporin in Hematopoietic Stem Cell Transplantation Patients. ( Ding, XL; Liu, LN; Miao, LY; Tian, JX; Xue, L; Yan, HH; Zhang, JJ; Zhang, WJ; Zhang, WW, 2019) |
| "The fluconazole V was increased in children supported by ECMO." | 2.80 | Fluconazole population pharmacokinetics and dosing for prevention and treatment of invasive Candidiasis in children supported with extracorporeal membrane oxygenation. ( Barrett, J; Benjamin, DK; Brouwer, KL; Capparelli, E; Cohen-Wolkowiez, M; Gonzalez, D; Wade, KC; Watt, KM, 2015) |
| " Although the clinical impact on efficacy and safety of the pharmacokinetic differences observed in this study was not established, it is desirable that fluconazole dosage regimens take into account both the gender and the bodyweight of the patient." | 2.73 | Gender differences in the oral pharmacokinetics of fluconazole. ( Carrasco-Portugal, Mdel C; Flores-Murrieta, FJ, 2007) |
| "Fluconazole (FCZ) is an antifungal bis-triazole with potent inhibitory effect on the principal CYP-dependent metabolic pathway of PHT." | 2.69 | Teratological interaction between the bis-triazole antifungal agent fluconazole and the anticonvulsant drug phenytoin. ( Bellati, U; Di Ilio, C; Giampietro, F; Iammarrone, E; Lamonaca, D; Tiboni, GM, 1999) |
| " Fluconazole was given in a mean dosage of 3." | 2.67 | Treatment of oropharyngeal candidiasis in HIV-infected children with oral fluconazole. Multicentre Study Group [corrected]. ( Marchisio, P; Principi, N, 1994) |
| " The mean fluconazole dosage was 3." | 2.67 | Fluconazole treatment of children with severe fungal infections not treatable with conventional agents. ( Fasano, C; Gibbs, D; O'Keeffe, J, 1994) |
| " The mean fluconazole dosage was 5." | 2.67 | Fluconazole treatment of neonates and infants with severe fungal infections not treatable with conventional agents. ( Fasano, C; Gibbs, D; O'Keeffe, J, 1994) |
| "Fluconazole is a novel orally-effective antifungal triazole which has been reported to have more specific effects on the cytochrome P-450 enzymes involved in fungal sterol synthesis." | 2.66 | Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives. ( Crook, D; Devenport, MH; Lees, LJ; Wynn, V, 1989) |
| " However, the extent to which inappropriate antifungal therapy is due to improper dosing or drug selection has not been well investigated." | 1.34 | Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. ( Bearden, DT; Garey, KW; Mingo, DE; Pai, MP; Rege, MD; Suda, KJ; Turpin, RS, 2007) |
| " Dose-response relationship was investigated by treating animals with 0 (vehicle), 87." | 1.33 | Murine teratology of fluconazole: evaluation of developmental phase specificity and dose dependence. ( Giampietro, F; Tiboni, GM, 2005) |
| "Amphotericin B was tested at 0." | 1.32 | Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis. ( Bauer, M; Graybill, JR; Larsen, RA; Thomas, AM, 2004) |
| " This study evaluated the antifungal efficacy of amphotericin B colloidal dispersion (ABCD) combined with flucytosine with and without fluconazole in a murine model of cryptococcal meningitis." | 1.30 | Amphotericin B colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine cryptococcal meningitis. ( Bauer, M; Daniel, BE; Diamond, DM; Ding, JC; Graybill, JR; Johnson, D; Larsen, RA; Leal, MA; Najvar, L; Thomas, AM; Williams, BK, 1998) |
| "Fluconazole is a novel azole antifungal agent with low lipophilicity and high metabolic stability which has been investigated pharmacokinetically in six animal species and in man." | 1.29 | Fluconazole: interspecies scaling and allometric relationships of pharmacokinetic properties. ( Jezequel, SG, 1994) |
| " Fluconazole appeared to be well absorbed from the gastrointestinal tract." | 1.29 | Pharmacokinetics of fluconazole in pediatric patients. ( Brammer, KW; Coates, PE, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (8.00) | 18.7374 |
| 1990's | 10 (40.00) | 18.2507 |
| 2000's | 7 (28.00) | 29.6817 |
| 2010's | 3 (12.00) | 24.3611 |
| 2020's | 3 (12.00) | 2.80 |
| Authors | Studies |
|---|---|
| Engbers, AGJ | 1 |
| Flint, RB | 1 |
| Voeller, S | 1 |
| Reiss, I | 1 |
| Liem, KD | 1 |
| Alffenaar, JC | 1 |
| Tibboel, D | 1 |
| Simons, S | 1 |
| Knibbe, CAJ | 2 |
| Brüggemann, RJ | 2 |
| Chen, L | 1 |
| van Rhee, KP | 1 |
| Wasmann, RE | 1 |
| Krekels, EHJ | 1 |
| Wiezer, MJ | 1 |
| van Dongen, EPA | 1 |
| Verweij, PE | 1 |
| van der Linden, PD | 1 |
| Xue, L | 1 |
| Zhang, WJ | 1 |
| Tian, JX | 1 |
| Liu, LN | 1 |
| Yan, HH | 1 |
| Zhang, WW | 1 |
| Ding, XL | 1 |
| Zhang, JJ | 1 |
| Miao, LY | 1 |
| Kitonsa, J | 1 |
| Nsubuga, R | 1 |
| Mayanja, Y | 1 |
| Kiwanuka, J | 1 |
| Nikweri, Y | 1 |
| Onyango, M | 1 |
| Anywaine, Z | 1 |
| Ggayi, AB | 1 |
| Kibengo, FM | 1 |
| Kaleebu, P | 1 |
| Day, J | 1 |
| Tesh, SA | 1 |
| Tesh, JM | 1 |
| Fegert, I | 1 |
| Buesen, R | 1 |
| Schneider, S | 1 |
| Mentzel, T | 1 |
| van Ravenzwaay, B | 1 |
| Stinchcombe, S | 1 |
| Watt, KM | 1 |
| Gonzalez, D | 1 |
| Benjamin, DK | 1 |
| Brouwer, KL | 1 |
| Wade, KC | 1 |
| Capparelli, E | 1 |
| Barrett, J | 1 |
| Cohen-Wolkowiez, M | 1 |
| Toda, F | 1 |
| Tanabe, K | 1 |
| Ito, S | 1 |
| Shinmura, H | 1 |
| Tokumoto, T | 1 |
| Ishida, H | 1 |
| Toma, H | 1 |
| Rajagopalan, P | 1 |
| Pelz, RK | 1 |
| Lipsett, PA | 1 |
| Swoboda, SM | 1 |
| Rinaldi, MG | 2 |
| Hendrix, CW | 1 |
| Larsen, RA | 4 |
| Bauer, M | 4 |
| Thomas, AM | 3 |
| Graybill, JR | 4 |
| Somchit, N | 1 |
| Norshahida, AR | 1 |
| Hasiah, AH | 1 |
| Zuraini, A | 1 |
| Sulaiman, MR | 1 |
| Noordin, MM | 1 |
| Tiboni, GM | 2 |
| Giampietro, F | 2 |
| Garey, KW | 1 |
| Pai, MP | 1 |
| Suda, KJ | 1 |
| Turpin, RS | 1 |
| Rege, MD | 1 |
| Mingo, DE | 1 |
| Bearden, DT | 1 |
| Carrasco-Portugal, Mdel C | 1 |
| Flores-Murrieta, FJ | 1 |
| Jezequel, SG | 1 |
| Brammer, KW | 1 |
| Coates, PE | 1 |
| Marchisio, P | 1 |
| Principi, N | 1 |
| Fasano, C | 2 |
| O'Keeffe, J | 2 |
| Gibbs, D | 2 |
| Weiner, JM | 1 |
| Diamond, DM | 3 |
| Leal, ME | 1 |
| Ding, JC | 3 |
| Leal, MA | 2 |
| Johnson, D | 2 |
| Williams, BK | 2 |
| Najvar, L | 2 |
| Daniel, BE | 1 |
| Laing, RB | 1 |
| Brettle, RP | 1 |
| Leen, CL | 1 |
| Iammarrone, E | 1 |
| Lamonaca, D | 1 |
| Bellati, U | 1 |
| Di Ilio, C | 1 |
| Devenport, MH | 1 |
| Crook, D | 1 |
| Wynn, V | 1 |
| Lees, LJ | 1 |
| Viscoli, C | 1 |
| Castagnola, E | 1 |
| Corsini, M | 1 |
| Gastaldi, R | 1 |
| Soliani, M | 1 |
| Terragna, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacokinetics of a Fluconazole Loading Dose in Infants and Toddlers[NCT00797420] | Phase 1 | 13 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 trials available for fluconazole and Body Weight
| Article | Year |
|---|---|
Multicenter-Based Population Pharmacokinetic Analysis of Ciclosporin in Hematopoietic Stem Cell Transplantation Patients.
Topics: Adolescent; Adult; Aged; Body Weight; Child; Child, Preschool; Cyclosporine; Dose-Response Relations | 2019 |
Determinants of two-year mortality among HIV positive patients with Cryptococcal meningitis initiating standard antifungal treatment with or without adjunctive dexamethasone in Uganda.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Anti-Inflammatory Agents; Antifungal A | 2020 |
Fluconazole population pharmacokinetics and dosing for prevention and treatment of invasive Candidiasis in children supported with extracorporeal membrane oxygenation.
Topics: Administration, Intravenous; Adolescent; Antifungal Agents; Body Weight; Candidiasis, Invasive; Chil | 2015 |
Enteral fluconazole population pharmacokinetics in patients in the surgical intensive care unit.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antifungal Agents; Biological Availability; Body Weight | 2003 |
Gender differences in the oral pharmacokinetics of fluconazole.
Topics: Administration, Oral; Antifungal Agents; Body Water; Body Weight; Chromatography, High Pressure Liqu | 2007 |
Treatment of oropharyngeal candidiasis in HIV-infected children with oral fluconazole. Multicentre Study Group [corrected].
Topics: Administration, Oral; Adolescent; AIDS-Related Opportunistic Infections; Body Weight; Candida; Candi | 1994 |
Fluconazole treatment of children with severe fungal infections not treatable with conventional agents.
Topics: Adolescent; Age Factors; AIDS-Related Opportunistic Infections; Body Weight; Candida; Candidiasis; C | 1994 |
Fluconazole treatment of neonates and infants with severe fungal infections not treatable with conventional agents.
Topics: Age Factors; Body Weight; Candida; Candidiasis; Female; Fluconazole; Humans; Infant; Infant, Low Bir | 1994 |
Teratological interaction between the bis-triazole antifungal agent fluconazole and the anticonvulsant drug phenytoin.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Antifungal Agents; Body Weight; Cleft Palate; | 1999 |
Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives.
Topics: Adult; Antifungal Agents; Apolipoproteins; Body Weight; Contraceptives, Oral, Hormonal; Female; Fluc | 1989 |
15 other studies available for fluconazole and Body Weight
| Article | Year |
|---|---|
Optimisation of fluconazole therapy for the treatment of invasive candidiasis in preterm infants.
Topics: Adult; Antifungal Agents; Body Weight; Candidiasis; Candidiasis, Invasive; Creatinine; Fluconazole; | 2022 |
Total bodyweight and sex both drive pharmacokinetic variability of fluconazole in obese adults.
Topics: Adult; Body Weight; Female; Fluconazole; Humans; Male; Mycoses; Obesity; Prospective Studies | 2022 |
Innovative selection approach for a new antifungal agent mefentrifluconazole (Revysol
Topics: Animals; Antifungal Agents; Body Weight; Dogs; Dose-Response Relationship, Drug; Female; Fluconazole | 2019 |
Tacrolimus trough level adjustment after administration of fluconazole to kidney recipients.
Topics: ABO Blood-Group System; Adult; Antifungal Agents; Area Under Curve; Blood Group Incompatibility; Bod | 2002 |
Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis.
Topics: Amphotericin B; Animals; Antifungal Agents; Body Weight; Brain; Colony Count, Microbial; Cryptococcu | 2004 |
Hepatotoxicity induced by antifungal drugs itraconazole and fluconazole in rats: a comparative in vivo study.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Antifungal Agents; Body Weight; Chemical and Dr | 2004 |
Murine teratology of fluconazole: evaluation of developmental phase specificity and dose dependence.
Topics: Abnormalities, Drug-Induced; Alcian Blue; Animals; Anthraquinones; Antifungal Agents; Body Weight; C | 2005 |
Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines.
Topics: Adult; Aged; Antifungal Agents; Body Weight; Candida; Candida glabrata; Candidiasis; Cohort Studies; | 2007 |
Fluconazole: interspecies scaling and allometric relationships of pharmacokinetic properties.
Topics: Animals; Biological Availability; Body Weight; Chemical Phenomena; Chemistry, Physical; Dogs; Flucon | 1994 |
Pharmacokinetics of fluconazole in pediatric patients.
Topics: Administration, Oral; Adolescent; Aging; Body Weight; Child; Child, Preschool; Fluconazole; Humans; | 1994 |
Effect of fluconazole on fungicidal activity of flucytosine in murine cryptococcal meningitis.
Topics: Animals; Antifungal Agents; Body Weight; Brain; Cryptococcus neoformans; Dose-Response Relationship, | 1996 |
Effect of severity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryptococcal meningitis.
Topics: Animals; Antifungal Agents; Body Weight; Cryptococcus neoformans; Disease Models, Animal; Drug Evalu | 1997 |
Amphotericin B colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine cryptococcal meningitis.
Topics: Amphotericin B; Animals; Body Weight; Brain; Drug Therapy, Combination; Fluconazole; Flucytosine; Ma | 1998 |
Clinical predictors of azole resistance, outcome and survival from oesophageal candidiasis in AIDS patients.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Body Weight; Candidiasis; CD4 Lymphocyte C | 1998 |
Fluconazole therapy in an underweight infant.
Topics: Body Weight; Candidiasis; Female; Fluconazole; Humans; Infant; Nutrition Disorders | 1989 |